stockrowTraws Pharma, Inc.
TRAW Healthcare Biotechnology
Traws Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, up 1,134.5% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −45.5%
- Free cash flow
- −25.5%
Quarter to June 2026, against a year earlier
Follow TRAW
Alert me
Traws Pharma, Inc. (TRAW) EV/Sales
As of 6 November 2026, Traws Pharma, Inc. (TRAW) trades at a EV/Sales of −0.5×. Over the past ten years it has ranged from −135× (March 2022) to 1,244× (February 2021); the current reading is higher than 47% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.9× | — |
| FY2024 | −33.4× | — |
| FY2023 | −18.8× | — |
| FY2022 | −106× | — |
| FY2021 | −53.7× | — |
| FY2020 | 269× | — |
| FY2019 | −7.9× | — |
| FY2018 | −6.7× | — |
| FY2017 | 12.0× | — |
| FY2016 | −2.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 1.9× | — |
| Jun 2025 | −1.5× | — |
| Mar 2025 | 0.4× | — |
| Dec 2024 | −33.4× | — |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LIPO Lipella Pharmaceuticals Inc. compare | −3.3× |
| TRAW Traws Pharma, Inc. | −0.5× |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| LIMN Liminatus Pharma Inc. compare | n/m |
| GRI GRI Bio, Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | 1.5× |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | 8.7× |
| ONCO Onconetix, Inc. compare | 14.6× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)